Analyzing CVRx (NASDAQ:CVRX) & Ainos (OTCMKTS:AIMD)

CVRx (NASDAQ:CVRX) and Ainos (OTCMKTS:AIMD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Volatility and Risk

CVRx has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Ainos has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500.

Earnings and Valuation

This table compares CVRx and Ainos”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$44.39 million	4.07	-$41.20 million	($2.47)	-3.38
Ainos	$65,122.00	52.52	-$14.01 million	($2.55)	-0.21

Ainos has lower revenue, but higher earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CVRx and Ainos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CVRx	-122.52%	-77.62%	-51.34%
Ainos	-515.80%	-44.32%	-40.35%

Institutional & Insider Ownership

75.3% of CVRx shares are held by institutional investors. Comparatively, 0.3% of Ainos shares are held by institutional investors. 18.9% of CVRx shares are held by company insiders. Comparatively, 4.6% of Ainos shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for CVRx and Ainos, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	0	2	5	0	2.71
Ainos	0	0	0	0	N/A

CVRx currently has a consensus price target of $13.67, indicating a potential upside of 63.48%. Given CVRx’s higher possible upside, equities research analysts plainly believe CVRx is more favorable than Ainos.

Summary

CVRx beats Ainos on 7 of the 13 factors compared between the two stocks.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.